Hormonal Contraceptives Considerations for Women with HIV and

  • Slides: 13
Download presentation
Hormonal Contraceptives – Considerations for Women with HIV and AIDS

Hormonal Contraceptives – Considerations for Women with HIV and AIDS

Hormonal Contraceptives • • Combined oral contraceptive pills (COCs) Progestin-only oral contraceptive pills (POPs)

Hormonal Contraceptives • • Combined oral contraceptive pills (COCs) Progestin-only oral contraceptive pills (POPs) Injectables (Depo-Provera/DMPA) Implants (Norplant, Jadelle, Sinoplant, Implanon)

Hormonal Contraceptive Methods: Appropriate for Women with HIV • Very effective • Easy to

Hormonal Contraceptive Methods: Appropriate for Women with HIV • Very effective • Easy to use • Suitable for short- or long-term use • Reversible • Non-contraceptive health benefits • Serious complications extremely rare

Overview: Theoretical Concerns about Hormonal Methods For women with HIV: • ARVs may reduce

Overview: Theoretical Concerns about Hormonal Methods For women with HIV: • ARVs may reduce method effectiveness or increase side effects • Contraceptives may affect ARV efficacy • Hormonal methods may possibly affect – infectivity – disease progression Future research may lead to changes in clinical practices. Source: Leitz, 2000; Piscitelli, 1996. ? ? ? 4

How ARVs Interact with COCs • May cause an increase or decrease of hormone

How ARVs Interact with COCs • May cause an increase or decrease of hormone levels • Some ARVs speed up liver metabolism and could lower blood levels of contraceptive hormones, may reduce method effectiveness • Not all ARV classes interact with contraceptive hormones (e. g. , NRTIs)

Interactions between COCs and PIs Contraceptive hormone levels in blood ARV levels in blood

Interactions between COCs and PIs Contraceptive hormone levels in blood ARV levels in blood Nelfinavir (NFV) No data Ritonavir (RTV) No data Lopinavir (LPV)/ Ritonavir (RTV) No data Atazanavir (ATV) No data Indinavir (IDV) No data Protease inhibitors Saquinavir (SQV) Source: WHO, 2004; Ouellet, 1998. No data No change

Interactions between COCs and NNRTIs Non-nucleoside reverse transcriptase inhibitors Contraceptive hormone levels in blood

Interactions between COCs and NNRTIs Non-nucleoside reverse transcriptase inhibitors Contraceptive hormone levels in blood ARV levels in blood Nevirapine (NVP) No change Efavirenz (EVF or EFZ) No change teratogen No significant interaction was found between ARV drugs and progestin-only injectables particularly DMPA. Source: WHO, 2004; Cohn, 2005.

Clinical Significance of COC/ARV Interaction Is Unknown • Studies examining clinical outcomes are needed

Clinical Significance of COC/ARV Interaction Is Unknown • Studies examining clinical outcomes are needed (i. e. , pregnancy rates, ovulation indicators) • No data on interaction between ARVs and hormonal contraceptives other than COCs and DMPA • Ritonavir-boosted protease inhibitors reduce contraceptive hormone blood levels considerably – not generally recommended for women on oral contraceptives or combined injectables – not part of first-line ARV regimens ? ? ? 4

Hormonal Contraceptive Use: Increases Risk of Cervical Infection DMPA COCs Increased risk of chlamydia

Hormonal Contraceptive Use: Increases Risk of Cervical Infection DMPA COCs Increased risk of chlamydia 3. 1 2. 2* Increased risk of cervicitis 1. 6 2. 3 * not statistically significant when adjusted for demographic factors Source: Lavreys, 2004.

Hormonal Contraceptive Use: May Increase HIV Shedding • HIV shedding may increase risk of

Hormonal Contraceptive Use: May Increase HIV Shedding • HIV shedding may increase risk of HIV transmission to partner • In one study, modest increase in cervical shedding of HIV-infected cells but no free virus • Impact on infectivity is uncertain ? ? ? 4 Source: Wang, 1999; Wang, 2004; John, 2001.

Relationships Require Further Research Using hormonal contraceptives may increase: Cervical STI infections may also

Relationships Require Further Research Using hormonal contraceptives may increase: Cervical STI infections may also increase cervical shedding of HIV More HIV virus may increase risk of transmission to partner • risk of acquiring cervical STIs • cervical shedding of HIV Future research may lead to changes in clinical practices. Source: Mc. Clelland, 2001; Ghys, 1997. ? ? ? 4

Hormonal Contraceptive Use: Theoretically May Affect Disease Progression Use of hormonal contraceptives near the

Hormonal Contraceptive Use: Theoretically May Affect Disease Progression Use of hormonal contraceptives near the time of HIV acquisition is associated with: • Higher viral load set point (indicator of disease progression) • Infection with multiple subtypes of HIV, resulting in faster CD 4 decline ? ? ? Future research may lead to changes in clinical practices. Viral load increases Immune system’s after initial infection killer cells respond Source: Lavreys, 2004; Sagar, 2003. 4 Viral load is reduced Higher set point Lower set point

Hormonal Contraceptive Use and HIV: What Providers Should Do • Counsel clients that certain

Hormonal Contraceptive Use and HIV: What Providers Should Do • Counsel clients that certain ARV drugs reduce blood levels of contraceptive hormones which in theory may reduce method effectiveness (except DMPA) • Encourage clients to tell providers which drugs they are taking • When there is a choice, prescribe ARV drugs that do not interact with hormonal methods • Encourage correct and consistent use of contraceptive method • Keep abreast of guideline updates